News

IMPENTRI IMI2Follow

Excited to announce that the clinical trial of Impentri in patients with #COVID19 associated ARDS has been approved. Hope to recruit the first patient soon.

Reply on Twitter 1357019438252515328 Retweet on Twitter 1357019438252515328 Like on Twitter 13570194382525153282 Twitter 1357019438252515328

14 Dec

Two highly relevant, recent @Nature papers have been published to deepen our understanding of the potential benefit of imatinib for the treatment of #Covid_19:
https://doi.org/10.1038/s41586-020-2901-9
and https://doi.org/10.1038/s41586-020-03065-y

Reply on Twitter 1338417061589086208 Retweet on Twitter 1338417061589086208 Like on Twitter 1338417061589086208 Twitter 1338417061589086208

24 Nov

Team at University of Maryland, Baltimore recently published their protocol for study of oral imatinib in hospitalized adults with COVID-19

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04819-9#MOESM1

Reply on Twitter 1331196748015001601 Retweet on Twitter 1331196748015001601 Like on Twitter 1331196748015001601 Twitter 1331196748015001601

Could this cancer drug fight fluid build-up in the lungs of COVID patients?

IMPENTRI will look for clinical proof of the benefit of imatinib in Covid-19 acute respiratory distress syndrome The build-up of fluid in the lungs is common among [...]

IMI2 Grant awarded to fund clinical study of imatinib in the treatment of COVID-19-associated ARDS

CAMBRIDGE, UK AND DUBLIN, IRELAND, May 13 2020 / / — Exvastat (Ireland) Ltd, a privately held biopharmaceutical company backed by Cambridge Innovation Capital, today announced the [...]